Payment overview · 2025
General Payments
$87.30
4 reported records · 3 companies
Healthcare provider profile · identity verified
Kimberly A Thompson, DO
Allopathic & Osteopathic Physicians|Family Medicine · MAQUOKETA, IA · NPI 1942252895
Verified facts
What the public records show
CMS Open Payments records show Kimberly A Thompson, DO received $87.30 in general payments during 2025 across 4 reported records.
PFIZER INC. accounted for 50.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.77 | 50.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.53 | 30.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.00 | 19.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $87.30 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.53 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 471 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 112 |
| Lisinopril | Lisinopril | 320 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 92 |
| Metformin Hcl | Metformin Hcl | 268 | 85 |
| Omeprazole | Omeprazole | 260 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 248 | 90 |
| Potassium Chloride | Potassium Chloride | 204 | 65 |
| Furosemide | Furosemide | 200 | 69 |
| Prednisone | Prednisone | 181 | 128 |
| Simvastatin | Simvastatin | 167 | 57 |
| Meloxicam | Meloxicam | 164 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 74 |
| Losartan Potassium | Losartan Potassium | 159 | 59 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 158 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 56 |
| Glipizide Er | Glipizide | 139 | 41 |
| Atenolol | Atenolol | 130 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 51 |
| Trazodone Hcl | Trazodone Hcl | 126 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 30 |
| Gabapentin | Gabapentin | 114 | 47 |
| Montelukast Sodium | Montelukast Sodium | 113 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 47 |
| Allopurinol | Allopurinol | 105 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 35 |
| Alprazolam | Alprazolam | 103 | 20 |
| Baclofen | Baclofen | 100 | 34 |
| Cephalexin | Cephalexin | 100 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 34 |
| Famotidine | Famotidine | 89 | 35 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 86 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 29 |
| Azithromycin | Azithromycin | 84 | 72 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 21 |
| Warfarin Sodium | Warfarin Sodium | 71 | 20 |
| Ozempic | Semaglutide | 67 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 20 |
| Ezetimibe | Ezetimibe | 62 | 20 |
| Sertraline Hcl | Sertraline Hcl | 62 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 25 |
| Lorazepam | Lorazepam | 60 | 12 |
| Metformin Hcl Er | Metformin Hcl | 60 | 26 |
| Lovastatin | Lovastatin | 59 | 22 |
| Alendronate Sodium | Alendronate Sodium | 57 | 17 |
| Tramadol Hcl | Tramadol Hcl | 57 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 20 |
| Amoxicillin | Amoxicillin | 55 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 18 |
| Januvia | Sitagliptin Phosphate | 52 | 18 |
| Terazosin Hcl | Terazosin Hcl | 50 | 13 |
| Bupropion Xl | Bupropion Hcl | 49 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 14 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Eliquis | Apixaban | 46 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 35 |
| Fluconazole | Fluconazole | 42 | 28 |
| Glimepiride | Glimepiride | 40 | 14 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Carvedilol | Carvedilol | 39 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 38 | 15 |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Spironolactone | Spironolactone | 37 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 18 |
| Buspirone Hcl | Buspirone Hcl | 34 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Nifedipine Er | Nifedipine | 31 | 12 |
| Gemfibrozil | Gemfibrozil | 29 | 11 |
| Irbesartan | Irbesartan | 29 | 12 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Glipizide | Glipizide | 27 | 11 |
| Levofloxacin | Levofloxacin | 27 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | 11 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 20 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Sulfasalazine | Sulfasalazine | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $87.30 · 4 records | PFIZER INC. | ABRYSVO, COMIRNATY, JARDIANCE, NURTEC ODT, PREVNAR 20, QULIPTA, UBRELVY, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error